PleoPharma Eyes History with First Cannabis Withdrawal Drug

NEW YORK, NY – March 30, 2026 – As the medical community grapples with the escalating public health challenge of Cannabis Use Disorder (CUD), a Phoenixville-based biotech is stepping into the spotlight. PleoPharma, Inc. has announced it will present at the upcoming Centri Capital Conference on April 14, a move that signals a critical juncture for the company as its lead drug candidate, PP-01, advances into late-stage Phase 3 clinical trials. The presentation offers more than a corporate update; it represents a potential turning point in addiction medicine, with PP-01 positioned to become the first-ever treatment approved by the Food and Drug Administration (FDA) for Cannabis Withdrawal Syndrome (CWS).

A Growing Crisis Meets a Potential Solution

The backdrop for PleoPharma's work is a silent epidemic. According to 2024 government data, an estimated 20 million Americans suffer from Cannabis Use Disorder, a condition characterized by an inability to stop using cannabis despite negative consequences. The number of individuals seeking treatment for cannabis-related health problems has surged, growing by an average of 28% annually between 2018 and 2023. This rise has exposed a significant gap in medical care: the lack of effective, approved tools to help those who want to quit.

For many, the primary barrier to cessation is Cannabis Withdrawal Syndrome. Symptoms, which can begin within a day of stopping use, include intense irritability, anxiety, debilitating insomnia, restlessness, and depressed mood. While not typically life-threatening, the severity of these symptoms can significantly impair daily functioning and is a primary driver of relapse.

An approved, standardized treatment would be a game-changer for both patients and clinicians who currently rely on behavioral therapies and a handful of off-label medications that offer limited and inconsistent relief. PleoPharma's PP-01 is being developed specifically to fill this void. By directly addressing the distressing symptoms of withdrawal, the treatment aims to provide a stable foundation upon which patients can engage with behavioral therapies and achieve long-term abstinence.

The Science Behind the Sobriety

The optimism surrounding PP-01 is grounded in promising clinical data. The drug, a once-daily oral product, has been granted Fast Track designation by the FDA, a status reserved for therapies that address serious conditions and fill an unmet medical need, allowing for an expedited review process.

This designation followed a successful Phase 2b study, a randomized, double-blind, placebo-controlled trial involving 234 participants. The results were statistically significant and clinically meaningful. Patients treated with PP-01 experienced a marked reduction in cannabis withdrawal symptoms compared to those who received a placebo. Critically, a key secondary endpoint revealed that patients on PP-01 had a five-fold greater rate of cannabis abstinence two weeks after treatment ended. Researchers also noted that a reduction in withdrawal symptoms during the first week was a strong predictor of future abstinence.

The investigational drug employs a dual-mechanism approach, formulated with tapering doses of nabilone and gabapentin. This combination is designed to target both the brain's suppressed CB1 receptors and the neurotransmitter dysregulation within the mesolimbic reward pathway that occurs during withdrawal. The Phase 2b trial also affirmed the drug's safety, reporting no serious adverse events and only mild, common side effects such as headache and fatigue.

The High-Stakes Biotech Gamble

Bringing a first-in-class drug to market is a monumental undertaking, and PleoPharma's journey highlights the high-stakes nature of biotech innovation. The company's presentation at the Centri Capital Conference is a strategic move to engage with the investors and partners necessary to fund the final, and most expensive, leg of its journey.

The market opportunity is substantial. The Cannabis Use Disorder treatment market was valued at approximately $1.65 billion in 2025 and is projected to grow to over $2.3 billion by 2030. As the potential first-to-market with an FDA-approved therapy, PleoPharma could capture a significant share of this expanding sector. This potential has not gone unnoticed by investors. Founded in 2019 by physicians Ginger and Jay Constantine, the company has raised over $60 million to date. This includes a crucial $36 million Series B financing round that closed in late 2025, with proceeds specifically earmarked to advance PP-01 into its pivotal Phase 3 trials.

While PleoPharma appears to be a front-runner, it is not entirely alone. Aelis Farma, in partnership with Indivior, is also developing a treatment for CUD, AEF0117, which targets the same CB1 receptor and recently completed its own Phase 2b trial. This emerging competition underscores the growing recognition of CUD as a viable and urgent therapeutic target for the pharmaceutical industry.

Navigating the Path to Approval

With financing in place and promising data in hand, PleoPharma now faces the rigors of Phase 3 clinical trials. This final stage of development involves larger, more extensive studies designed to confirm the drug's efficacy and safety in a broader patient population, providing the definitive evidence needed for an FDA submission. Success in Phase 3 is the last major hurdle before the company can file a New Drug Application (NDA).

If PP-01 successfully navigates this process and secures approval, it would represent a paradigm shift in addiction treatment. Clinicians would have a validated, evidence-based tool to manage the acute physical and psychological distress of withdrawal, improving patient retention in treatment programs and increasing the odds of sustained recovery. For the millions of individuals struggling to break the cycle of cannabis dependence, it could offer a tangible new source of hope. The upcoming presentation in New York will be closely watched by investors, clinicians, and potential patients alike, as it offers a glimpse into a future where cannabis addiction is treated not just with support, but with science.